We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

225 hedge funds and large institutions have $3.27B invested in Neurocrine Biosciences in 2016 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 97 increasing their positions, 75 reducing their positions, and 41 closing their positions.

New
Increased
Maintained
Reduced
Closed

97.13% more ownership

Funds ownership: 0% → 97.13% (+97%)

29% more repeat investments, than reductions

Existing positions increased: 97 | Existing positions reduced: 75

6% less call options, than puts

Call options by funds: $23.6M | Put options by funds: $25.1M

8% less funds holding

Funds holding: 244 → 225 (-19)

14% less funds holding in top 10

Funds holding in top 10: 7 → 6 (-1)

24% less capital invested

Capital invested by funds: $4.32B → $3.27B (-$1.05B)

37% less first-time investments, than exits

New positions opened: 26 | Existing positions closed: 41

Holders
225
Holders Change
-19
Holders Change %
-7.79%
% of All Funds
5.63%
Holding in Top 10
6
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-14.29%
% of All Funds
0.15%
New
26
Increased
97
Reduced
75
Closed
41
Calls
$23.6M
Puts
$25.1M
Net Calls
-$1.48M
Net Calls Change
-$32.7M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$55.6M
2
HM
HealthCor Management
New York
+$44.8M
3
PA
Perceptive Advisors
New York
+$38M
4
Franklin Resources
Franklin Resources
California
+$18M
5
GPP
Great Point Partners
Connecticut
+$16.1M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$153M
2
EAM
Eagle Asset Management
Florida
-$46.3M
3
Citadel Advisors
Citadel Advisors
Florida
-$35.2M
4
American Century Companies
American Century Companies
Missouri
-$25.8M
5
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
BG
76
BlackRock Group
United Kingdom
$5.56M -$7.01M -154,804 -52%
Public Employees Retirement Association of Colorado
77
Public Employees Retirement Association of Colorado
Colorado
$5.55M +$5.6M +123,740 +632%
Swiss National Bank
78
Swiss National Bank
Switzerland
$5.52M +$109K +2,400 +2%
TD Asset Management
79
TD Asset Management
Ontario, Canada
$5.14M -$3.04M -67,105 -34%
EAM
80
Eventide Asset Management
Massachusetts
$4.84M – – –
Massachusetts Financial Services
81
Massachusetts Financial Services
Massachusetts
$4.81M -$14K -309 -0.2%
Wells Fargo
82
Wells Fargo
California
$4.71M +$2.89M +63,931 +110%
NC
83
Nexthera Capital
New York
$4.64M +$5.43M +120,000 New
RhumbLine Advisers
84
RhumbLine Advisers
Massachusetts
$4.15M +$348K +7,681 +8%
GH
85
GAM Holding
Switzerland
$4.12M +$4.82M +106,500 New
NFA
86
Nationwide Fund Advisors
Ohio
$4.05M +$2.44M +53,960 +106%
Barclays
87
Barclays
United Kingdom
$3.9M +$4.22M +93,196 +1,256%
Handelsbanken Fonder
88
Handelsbanken Fonder
Sweden
$3.87M – – –
State Board of Administration of Florida Retirement System
89
State Board of Administration of Florida Retirement System
Florida
$3.57M +$310K +6,859 +8%
GKIM
90
GW&K Investment Management
Massachusetts
$3.34M +$279K +6,169 +8%
Two Sigma Investments
91
Two Sigma Investments
New York
$3.25M +$3.8M +83,923 New
AA
92
ALPS Advisors
Colorado
$3.23M -$1.23M -27,113 -25%
DekaBank Deutsche Girozentrale
93
DekaBank Deutsche Girozentrale
Germany
$3.18M -$3.24M -71,500 -46%
GC
94
Guggenheim Capital
Illinois
$3.18M -$291K -6,420 -7%
TA
95
Teachers Advisors
New York
$3.03M +$211K +4,668 +6%
Principal Financial Group
96
Principal Financial Group
Iowa
$2.95M +$244K +5,386 +8%
BIM
97
BlackRock Investment Management
Delaware
$2.91M -$567K -12,519 -14%
BG
98
Bellevue Group
Switzerland
$2.9M +$770K +17,000 +29%
MOACM
99
Mutual of America Capital Management
New York
$2.81M +$30.3K +670 +0.9%
SCA
100
Secor Capital Advisors
New York
$2.77M +$3.01M +66,447 +1,292%
2 3
4
5 6

NBIX Hedge Fund Activity: Q4 2016 in Review

225 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2016, worth a combined $3.27B — down 24% from $4.32B a quarter earlier.

Sellers outnumbered buyers: 41 funds closed out of NBIX and 26 opened new positions — a net loss of 15 holders — while 75 trimmed existing stakes and 97 added.

The largest buyer was Millennium Management, adding an estimated $55.6M. The largest seller was T. Rowe Price Associates, cutting an estimated $153M.

  • 225 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2016, down from 244 in Q3 2016.
  • Funds reported $3.27B of Neurocrine Biosciences stock for Q4 2016, down 24% quarter-over-quarter.
  • 26 funds opened new Neurocrine Biosciences positions in Q4 2016 and 41 closed out, a net change of -15 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2016 was Millennium Management, an estimated $55.6M added.
  • The largest Neurocrine Biosciences seller in Q4 2016 was T. Rowe Price Associates, an estimated $153M sold.

Based on aggregated 13F filings for Q4 2016.